MRI/MRSI in Risk Assessment of Prostate Cancer Patients
In this study, patients with low-risk, organ-confined prostate cancer identified in clinic
or prior to their already scheduled standard of care MRI in the Department of Radiology will
be approached for the study. Eligible patients will undergo a baseline eMRI/MRSI exam
between 6 and 24 weeks following biopsy. Patients will undergo definitive treatment (radical
prostatectomy (RP) or radiation therapy (RT)) or will be placed on deferred therapy.
Predictor variables will be recorded for each patient after enrollment, before treatment and
during treatment follow-up. Patient outcome-disease progression will be determined by long
term clinical follow-up
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
In a population of patients designated as clinically indolent by NCCN guidelines, we will evaluate the ability of eMRI/MRSI to predict pathologically indolent cancer. eMRI/MRSI findings will be compared with step-section pathology.
Hedvig Hricak, M.D., Ph.D
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|